P21

≥98% HPLCCOA per batchCold-chain shippedIn-house synthesisResearch use only · not for human consumption

Price range: $63.99 through $79.99

Independently verified Tested by IRZC Laboratories Batch NHV26-P8196 · Purity 99.06 % HPLC · Issued 4 Aug 2026 · Cert COA-VXQ0-4F0W-MVerify at IRZCVerifyScan to verify

A tetrapeptide mimetic of ciliary neurotrophic factor (CNTF) with an adamantane C-terminal modification, designed to cross the blood-brain barrier and promote neurogenesis.

FormulaC27H42N6O8
Mol. weight578.66 g/mol
FormLyophilised powder
2 People watching this product now!
SKU: PEP-050 Category:

Molecular & analytical data

Verified chemistry and third-party reference identifiers for this compound.

Amino acid sequenceAc-Asp-Gly-Gly-Leu-(adamantyl)Gly-NH2 — published as Ac-DGGL(A)G-NH2: a DGGL core with a C-terminal adamantylated glycine
Molecular formulaC27H42N6O8
Molecular weight578.66 g/mol
CAS number1246751-68-7
Purity standard≥98%
Half-life~2–4 hours (estimated based on peptide degradation)
BioavailabilityCNS delivery via intranasal route; subcutaneous bioavailability not fully characterized
Origin / sourceSynthetic; derived from CNTF sequence (Genebank/UniProt); developed by researchers at New York State Institute for Basic Research
Year discovered2010s (development as CNTF mimetic)

Reconstitution calculator

Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →

Concentration— mg/mL— mcg per unit
—Draw tounits on a U-100 syringe
—Volume / drawmL
—Complete drawsper vial

—

A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.

Quality & verification

Every batch is characterised before release and ships with documentation.

≥98%HPLC purity
578.66 g/molMolecular weight
MS + HPLCIdentity & purity assay
Third-party testedBatches are tested by IRZC Laboratories — independent HPLC + mass-spec confirms identity and purity against that product’s release specification.
Batch-matched COAA certificate of analysis is issued per batch and matched to your vial’s lot number.
Cold-chain fulfilmentLyophilised product is packed with insulated, temperature-controlled shipping.
Controlled synthesisProduced under documented, reproducible in-house processes with lot traceability.

Storage & handling

Keep the peptide stable from delivery through reconstitution.

1
On arrivalStore the sealed, lyophilised vial frozen at −20°C, protected from light and moisture.
2
ReconstitutionAdd bacteriostatic water down the vial wall; swirl gently — do not shake. Use the calculator above to plan volume.
3
After mixingRefrigerate the reconstituted solution at 2–8°C and use within the stability window below.
4
HandlingWork in a clean area, wipe the stopper with alcohol, and avoid repeated freeze–thaw cycles.
Manufacturer storage note

Lyophilized: room temperature; reconstituted: −20°C; nasal spray solutions: refrigerate 2–8°C

Description

P21 (also written P021) is a synthetic tetrapeptide derived from the most bioactive region of ciliary neurotrophic factor (CNTF), specifically residues 148–151, modified with an adamantylated glycine at the C-terminus. This dual modification—adamantane group and N-terminal acetylation—dramatically improves blood-brain barrier (BBB) penetration by reducing polarity and resistance to exopeptidase degradation, allowing intranasal or subcutaneous administration with central nervous system delivery. CNTF naturally promotes neuron survival, neurite outgrowth, and neurogenesis, but its full-length protein cannot cross the BBB effectively. P21 retains the core neurotrophic signaling capability by acting on JAK/STAT and MAPK/ERK pathways via the CNTF receptor complex. Preclinical studies demonstrate that P21 increases adult hippocampal neurogenesis, improves spatial memory in cognitively impaired rodents, and shows benefits in models of Alzheimer’s disease by reducing tau phosphorylation and amyloid burden. Research in CDKL5 deficiency disorder models has also shown promise. P21 is investigated as a nootropic and neuroprotective agent.

Certificates of Analysis

Certificates of Analysis

Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.

Batch #IssuedPurityCertificate
NHV26-P8196
COA-VXQ0-4F0W-M
04 Aug 202699.06 % HPLCVerify at IRZC ↗

“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.

Research & Literature
Reported in research literature — not usage guidance.

The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.

Mechanism of action

In published preclinical work P021 acts by competitively inhibiting leukemia inhibitory factor (LIF) signalling — a negative regulator of neurogenesis — rather than by agonising the CNTF receptor complex; it increases BDNF expression, reported to act through TrkB–PI3K–AKT signalling with downstream inhibition of GSK-3β; promotes hippocampal neurogenesis, neurite outgrowth and synaptic plasticity; reduces tau hyperphosphorylation; crosses the BBB via adamantane-mediated lipophilicity.

Primary uses / indications

Cognitive decline; neurogenesis support; Alzheimer's disease (preclinical); CDKL5 deficiency disorder (preclinical); nootropic use; neuroprotection after CNS injury

Typical dosage (reported)

200–400 mcg/day intranasal (research protocols)

Cycle duration (reported)

4–8 weeks typical research cycle

Administration route

Intranasal spray (primary research route); subcutaneous injection

Side effects (reported)

Generally well tolerated in animal studies; limited human safety data; potential headache; unknown long-term effects

Contraindications

Limited human data; pregnancy and lactation (avoid); concurrent SSRI/SNRI (theoretical interaction)

Drug interactions

Potential interactions with JAK inhibitors; additive neurogenic effects with Semax; theoretical serotonergic interaction

Reviews (0)
0 reviews
0
0
0
0
0

There are no reviews yet.

Be the first to review “P21”

Your email address will not be published. Required fields are marked *

You have to be logged in to be able to add photos to your review.

Specifications

Identity

Full name / brand namesP21; P021; CNTF Peptide Mimetic; Neurogenesis Peptide
CategoryCognitive & Neuroprotective
SubcategoryNeurogenesis Peptide
Origin / sourceSynthetic; derived from CNTF sequence (Genebank/UniProt); developed by researchers at New York State Institute for Basic Research
Year discovered2010s (development as CNTF mimetic)

Chemistry

Amino acid sequenceAc-Asp-Gly-Gly-Leu-(adamantyl)Gly-NH2 — published as Ac-DGGL(A)G-NH2: a DGGL core with a C-terminal adamantylated glycine
Molecular formulaC27H42N6O8
Molecular weight578.66 g/mol
CAS number1246751-68-7
Purity standard≥98%

Pharmacokinetics

Half-life~2–4 hours (estimated based on peptide degradation)
BioavailabilityCNS delivery via intranasal route; subcutaneous bioavailability not fully characterized

Regulatory & research status

FDA statusNot FDA approved; research compound
Prescription requiredNo (research use only)
Research statusPreclinical (animal studies); early research phase
Clinical trialsNo registered clinical trials as of 2026

References

1. Kazim SF, Blanchard J, Dai CL, et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014;71:110-130. PMID 25046994. 2. Mottolese N, Loi M, Trazzi S, et al. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. J Neurodev Disord. 2024;16(1):65. doi:10.1186/s11689-024-09583-4.

Frequently asked questions

What is P21?
A tetrapeptide mimetic of ciliary neurotrophic factor (CNTF) with an adamantane C-terminal modification, designed to cross the blood-brain barrier and promote neurogenesis.
How does P21 work?
Reported in the research literature: In published preclinical work P021 acts by competitively inhibiting leukemia inhibitory factor (LIF) signalling — a negative regulator of neurogenesis — rather than by agonising the CNTF receptor complex; it increases BDNF expression, reported to act through TrkB–PI3K–AKT signalling with downstream…
What P21 dosage is used in research?
For laboratory research reference only, not usage guidance: 200–400 mcg/day intranasal (research protocols)
What is the half-life of P21?
The reported biological half-life of P21 is approximately ~2–4 hours (estimated based on peptide degradation).
How should P21 be stored and reconstituted?
NHOV ships P21 as a lyophilised powder. Store unopened vials at −20 °C. Reconstitute with bacteriostatic water; once reconstituted, refrigerate at 2–8 °C, protect from light, and use within the bacteriostatic-water shelf window. Use the NHOV reconstitution calculator to find the exact volume for your target concentration.
What purity is NHOV's P21?
NHOV P21 is released against a specification of ≥98%, verified by HPLC with mass-spectrometry identity confirmation, and ships with a batch-specific Certificate of Analysis (COA) matched to the vial's lot number.
Is P21 approved for human use?
No. P21 is sold strictly for laboratory and scientific research use only. It is not for human or veterinary consumption and is not approved as a drug.